Anxiety and depression among racial/ethnic minorities and impoverished women testing positive for BRCA1/2 mutations in the United States.
Anxiety
BRCA1
BRCA2
Depression
Disparities
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
12
01
2022
accepted:
22
03
2022
pubmed:
29
3
2022
medline:
31
5
2022
entrez:
28
3
2022
Statut:
ppublish
Résumé
To outline the association between race/ethnicity and poverty status and perceived anxiety and depressive symptomologies among BRCA1/2-positive United States (US) women to identify high-risk groups of mutation carriers from medically underserved backgrounds. A total of 211 BRCA1/2-positive women from medically underserved backgrounds were recruited through national Facebook support groups and completed an online survey. Adjusted odds ratios (aOR) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression for associations between race/ethnicity, poverty status, and self-reported moderate-to-severe anxiety and depressive symptoms. Women ranged in age (18-75, M = 39.5, SD = 10.6). Most women were non-Hispanic white (NHW) (67.2%) and were not impoverished (76.7%). Hispanic women with BRCA1/2 mutations were 6.11 times more likely to report moderate-to-severe anxiety (95% CI, 2.16-17.2, p = 0.001) and 4.28 times more likely to report moderate-to-severe depressive symptoms (95% CI, 1.98-9.60, p < 0.001) than NHW women with these mutations. Associations were not statistically significant among other minority women. Women living in poverty were significantly less likely to report moderate-to-severe depressive symptoms than women not in poverty (aOR, 0.42, 95% CI, 0.18-0.95, p = 0.04). Hispanic women with BRCA1/2 mutations from medically underserved backgrounds are an important population at increased risk for worse anxiety and depressive symptomology. Our findings among Hispanic women with BRCA1/2 mutations add to the growing body of literature focused on ethnic disparities experienced across the cancer control continuum.
Identifiants
pubmed: 35344102
doi: 10.1007/s00520-022-07004-7
pii: 10.1007/s00520-022-07004-7
pmc: PMC10083824
mid: NIHMS1885026
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5769-5778Subventions
Organisme : NCI NIH HHS
ID : T32 CA009314
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
American Cancer Society (ACS) (2020). Family cancer syndromes. https://www.cancer.org/cancer/cancer-causes/genetics/family-cancer-syndromes.html .
Godet I, Gilkes DM (2017) BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther 4(1):10. https://doi.org/10.15761/ICST.1000228
Mersch J, Jackson MA, Park M et al (2015) Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121(14):269–275. https://doi.org/10.1002/cncr.29357
doi: 10.1002/cncr.29357
pubmed: 25224030
Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://doi.org/10.1001/jama.2017.7112
Song Y, Barry WT, Seah DS et al (2020) Patterns of recurrence and metasasis in BRCA1/BRCA2-associated breast cancers. Cancer 126(2):271–280. https://doi.org/10.1002/cncr.32540
doi: 10.1002/cncr.32540
pubmed: 31581314
Haque R, Shi JM, Telford C, et al (2018) Survival outcomes in BRCA1 or BRCA2 mutation carriers and the influence of triple-negative breast cancer subtype. Perm J 22:170–197. https://doi.org/10.7812/TPP/17-197
Lafourcade A, His M, Baglietto L et al (2018) Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort. BMC Cancer 18(1):171. https://doi.org/10.1186/s12885-018-4076-4
doi: 10.1186/s12885-018-4076-4
pubmed: 29426294
pmcid: 5807734
Mau C, Untch M (2017) Prophylactic surgery: for whom, when and how. Breast Care 12:379–384. https://doi.org/10.1159/000485830
doi: 10.1159/000485830
pubmed: 29456469
pmcid: 5803721
Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL (2016) Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg 212(4):660–669. https://doi.org/10.1016/j.amjsurg.2016.06.010
doi: 10.1016/j.amjsurg.2016.06.010
pubmed: 27649974
van Zelst JCM, Mus RDM, Woldringh G et al (2017) Surveillance of women with the BRCA1 or BRCA2 mutation by using biannual automated breast US, MR imaging, and mammography. Radiol 285(2):376–388. https://doi.org/10.1148/radiol.2017161218
doi: 10.1148/radiol.2017161218
Glassey R, O’Connor M, Ives A et al (2018) Heightened perception of breast cancer risk in young women at risk of familial breast cancer. Fam Cancer 17:15–22. https://doi.org/10.1007/s10689-017-0001-2
doi: 10.1007/s10689-017-0001-2
pubmed: 28501958
Ringwald J, Wochnowski C, Bosse K et al (2016) Psychological distress, anxiety, and depression of cancer-affected BRCA1/2 mutation carriers: a systematic review. J Genet Couns 25(5):880–891. https://doi.org/10.1007/s10897-016-9949-6
doi: 10.1007/s10897-016-9949-6
pubmed: 27074860
Harmsen MG, Hermens RPMG, Prins JB, Hoogerbrugge N, de Hullu JA (2015) How medical choices influence quality of life of women carrying a BRCA mutation. Crit Rev Oncol Hematol 96(3):555–568. https://doi.org/10.1016/j.critrevonc.2015.07.010
doi: 10.1016/j.critrevonc.2015.07.010
pubmed: 26299336
Manoukian S, Alfieri S, Bianchi E et al (2019) Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: are there factors associated with the choice? Psycho-Oncol 28(9):1871–1878. https://doi.org/10.1002/pon.5166
doi: 10.1002/pon.5166
Borreani C, Manoukian S, Bianchi E et al (2013) The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers. Clin Genet 85(1):7–15. https://doi.org/10.1111/cge.12298
doi: 10.1111/cge.12298
pubmed: 24117034
Dean M, Scherr CL, Clements M et al (2017) “When information is not enough”: a model for understanding BRCA-positive previvors’ information needs regarding hereditary breast and ovarian cancer risk. Patient Educ Couns 100(9):1738–1743. https://doi.org/10.1016/j.pec.2017.03.013
doi: 10.1016/j.pec.2017.03.013
pubmed: 28385363
Hoberg-Vetti H, Bjorvatn C, Fiane BE et al (2016) BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counseling: the DNA-BONus study. Eur J Hum Genet 24(6):881–888. https://doi.org/10.1038/ejhg.2015.196
doi: 10.1038/ejhg.2015.196
pubmed: 26350514
Mella S, Muzzatti B, Dolcetti R, Annunziata MA (2017) Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study. Hered Cancer Clin Pract 15:16. https://doi.org/10.1186/s13053-017-0077-6
den Heijer M, Seynaeve C, Vanheusden K et al (2012) Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile. Psycho-Oncol 22(3):598–604. https://doi.org/10.1002/pon.3039
doi: 10.1002/pon.3039
Cannioto R (2020) Investigating contributions of physical inactivity and obesity to racial disparities in cancer risk and mortality warrants more consideration. J Natl Cancer Inst 113(6):647–649. https://doi.org/10.1093/jnci/djaa189
doi: 10.1093/jnci/djaa189
pmcid: 8168126
Williams CD, Bullard AJ, O’Leary M, Thomas R, Redding TS IV, Goldstein K (2019) Racial/ethnic disparities in BRCA counseling and testing: a narrative review. J Racial Ethn Health Disparities 6(3):570–583. https://doi.org/10.1007/s40615-018-00556-7
doi: 10.1007/s40615-018-00556-7
pubmed: 30963508
Jones T, Freeman K, Ackerman M et al (2020) Mental illness and BRCA1/2 genetic testing intention among multiethnic women undergoing screening mammography. Oncol Nurs Forum 47(1):E13–E24. https://doi.org/10.1188/20.onf.e13-e24
doi: 10.1188/20.onf.e13-e24
pubmed: 31845917
pmcid: 7295180
Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208. https://doi.org/10.1016/j.jbi.2019.103208
doi: 10.1016/j.jbi.2019.103208
pubmed: 31078660
pmcid: 7254481
US Census Bureau (2020). How the Census Bureau measures poverty. https://www.census.gov/topics/income-poverty/poverty/guidance/poverty-measures.html .
Lowe B, Decker O, Muller S et al (2008) Validation and standardization of the Generalized Anxiety Disorder screener (GAD-7) in the general population. Med Care 46(3):266–274. https://doi.org/10.1097/mlr.0b013e318160d093
doi: 10.1097/mlr.0b013e318160d093
pubmed: 18388841
Spitzer RL, Kroenke K, Williams JBW (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166(10):1092–1097. https://doi.org/10.1001/archinte.166.10.1092
doi: 10.1001/archinte.166.10.1092
pubmed: 16717171
Kroenke K, Spitzer RL, Williams JBW (2001) The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 16(9):606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x
doi: 10.1046/j.1525-1497.2001.016009606.x
pubmed: 11556941
pmcid: 1495268
StataCorp, Inc (2019). Stata Statistical Software: Release 16. College Station, TX.
Nelson HD, Pappas M, Cantor A, Haney E, Holmes R (2019) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 322(7):666–685. https://doi.org/10.1001/jama.2019.8430
doi: 10.1001/jama.2019.8430
pubmed: 31429902
Yeomans Kinney A, Gammon A, Coxworth J et al (2010) Exploring attitudes, beliefs, and communication preferences of Latino community members regarding BRCA1/2 mutation testing and preventive strategies. Genet Med 12(2):105–115. https://doi.org/10.1097/gim.0b013e3181c9af2d
doi: 10.1097/gim.0b013e3181c9af2d
Parente DJ (2020) BRCA-related cancer genetic counseling is indicated in many women seeking primary care. J Am Board Fam Med 33(6):885–893. https://doi.org/10.3122/jabfm.2020.06.190461
doi: 10.3122/jabfm.2020.06.190461
pubmed: 33219067
Thompson HS, Sussner K, Schwartz MD et al (2012) Receipt of genetic counseling recommendations among black women at high risk for BRCA mutations. Genet Test Mol Biomarkers 16(11):1257–1262. https://doi.org/10.1089/gtmb.2012.0114
doi: 10.1089/gtmb.2012.0114
pubmed: 23057569
Levy DE, Byfield SD, Comstock CB et al (2011) Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genet Med 13(4):349–355. https://doi.org/10.1097/gim.0b013e3182091ba4
doi: 10.1097/gim.0b013e3182091ba4
pubmed: 21358336
pmcid: 3604880
McGuinness JE, Trivedi MS, Silverman T et al (2019) Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population. Cancer Genet 235–236:72–76. https://doi.org/10.1016/j.cancergen.2019.04.063
doi: 10.1016/j.cancergen.2019.04.063
pubmed: 31078448
pmcid: 6625883
Lagos-Jaramillo VI, Press MF, Ricker CN, et al (2011) Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Res Treat 130(1):281–289. https://doi.org/10.1007/s10549-011-1570-7
Hull LE, Haas JS, Simon SR (2018) Provider discussions of genetic tests with U.S. women at right for a BRCA mutation. Am J Prev Med 54(2):221–228. https://doi.org/10.1016/j.amepre.2017.10.015
Guo F, Scholl M, Fuchs EL, et al (2020). Trends in positive BRCA test results among older women in the United States, 2008–2018. JAMA Network Open, 3(11):e2024358. http://jamanetwork.com/article.aspx?doi= https://doi.org/10.1001/jamanetworkopen.2020.24358
Moses T, Landefeld R (2019). Addressing behavioral health and cancer in Hispanic/Latino populations. https://www.bhthechange.org/resources/addressing-behavioral-health-and-cancer-in-hispanic-latino-populations/ .
Rubinsak LA, Kleinman A, Quillin J et al (2019) Awareness and acceptability of population-based screening for pathogenic BRCA variants: do race and ethnicity matter? Gynecol Oncol 154(2):383–387. https://doi.org/10.1016/j.ygyno.2019.06.009
doi: 10.1016/j.ygyno.2019.06.009
pubmed: 31239069
Hurtado-de-Mendoza A, Graves K, Gomez-Trillos S et al (2018) Provider’s perceptions of barriers and facilitators for Latinas to participate in genetic cancer risk assessment for hereditary breast and ovarian cancer. Healthcare 6(3):116. https://doi.org/10.3390/healthcare6030116
doi: 10.3390/healthcare6030116
pmcid: 6164735
Sussner KM, Jandorf L, Thompson HS, Valdimarsdottir HB (2013) Barriers and facilitators to BRCA genetic counseling among at-risk Latinas in New York City. Psycho-Oncol 22(7):1594–1604. https://doi.org/10.1002/pon.3187
doi: 10.1002/pon.3187
Sussner KM, Edwards T, Villagra C, et al (2010) Interest and beliefs about BRCA genetic counseling among at-risk Latinas in New York City. J Genet Couns 19(3):255–268. https://doi.org/10.1007/2Fs10897-014-9746-z
Augusto B, Kasting ML, Couch FJ et al (2019) Current approaches to cancer genetic counseling services for Spanish-speaking patients. J Immigr Minor Health 21(2):434–437. https://doi.org/10.1007/s10903-018-0772-z
doi: 10.1007/s10903-018-0772-z
pubmed: 29882171
pmcid: 6730643
Trottier M, Lunn J, Butler R et al (2015) Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas. Clin Genet 88(2):182–186. https://doi.org/10.1111/cge.12468
doi: 10.1111/cge.12468
pubmed: 25060751
Houlihan MC, Tariman JD (2017). Comparison of outcome measures for traditional and online support groups for breast cancer patients: an integrative literature review. J Adv Pract Oncol 8(4): 348–359. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040879